Aarti Drugs Limited Stock EBITDA
| AARTIDRUGS | 449.25 5.50 1.21% |
Aarti Drugs Limited fundamentals help investors to digest information that contributes to Aarti Drugs' financial success or failures. It also enables traders to predict the movement of Aarti Stock. The fundamental analysis module provides a way to measure Aarti Drugs' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aarti Drugs stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | 3.2 B | 2 B |
Aarti | EBITDA |
Aarti Drugs Limited Company EBITDA Analysis
Aarti Drugs' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Aarti Drugs EBITDA | 3.25 B |
Most of Aarti Drugs' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aarti Drugs Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Aarti Ebitda
Ebitda |
|
According to the company disclosure, Aarti Drugs Limited reported earnings before interest,tax, depreciation and amortization of 3.25 B. This is 270.24% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The ebitda for all India stocks is 16.67% higher than that of the company.
Aarti EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aarti Drugs' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aarti Drugs could also be used in its relative valuation, which is a method of valuing Aarti Drugs by comparing valuation metrics of similar companies.Aarti Drugs is currently under evaluation in ebitda category among its peers.
Aarti Fundamentals
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0617 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 47.2 B | ||||
| Shares Outstanding | 91.27 M | ||||
| Shares Owned By Insiders | 61.84 % | ||||
| Shares Owned By Institutions | 9.50 % | ||||
| Price To Book | 3.25 X | ||||
| Price To Sales | 1.73 X | ||||
| Revenue | 25.29 B | ||||
| Gross Profit | 8.06 B | ||||
| EBITDA | 3.25 B | ||||
| Net Income | 1.71 B | ||||
| Total Debt | 5.64 B | ||||
| Book Value Per Share | 139.96 X | ||||
| Cash Flow From Operations | 3.59 B | ||||
| Earnings Per Share | 16.55 X | ||||
| Target Price | 555.0 | ||||
| Number Of Employees | 1.06 K | ||||
| Beta | 0.83 | ||||
| Market Capitalization | 41.09 B | ||||
| Total Asset | 24.32 B | ||||
| Retained Earnings | 11.55 B | ||||
| Working Capital | 5.25 B | ||||
| Annual Yield | 0 % | ||||
| Net Asset | 24.32 B |
About Aarti Drugs Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aarti Drugs Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aarti Drugs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aarti Drugs Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Aarti Stock Analysis
When running Aarti Drugs' price analysis, check to measure Aarti Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aarti Drugs is operating at the current time. Most of Aarti Drugs' value examination focuses on studying past and present price action to predict the probability of Aarti Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aarti Drugs' price. Additionally, you may evaluate how the addition of Aarti Drugs to your portfolios can decrease your overall portfolio volatility.